Lanreotide Acetate Injection
Product Images NDC 69097-908

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 39 technical images submitted to the FDA as part of the official labeling for Lanreotide Acetate (NDC 69097-908). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A Kaplan-Meier curve chart showing progression-free survival probability (%) over time (months) comparing Lanreotide Injection and placebo groups. The chart includes survival probability on the vertical axis and time in months on the horizontal axis, with a table below indicating the number of subjects still at risk at various time points for both groups.*
FDA Label Image

Figure 10 (Figure 10)

Figure 10 (Figure 10)
Label for LANREOTIDE ACETATE injection shows a syringe with a white label. The label includes the text "Lanreotide acetate mg/xxml," along with placeholders for expiration date and lot number. The syringe design includes a plunger and a needle cover, and the product is presented for subcutaneous use by Cipla USA Inc.*
FDA Label Image

Figure 11 (Figure 11)

Figure 11 (Figure 11)
An instructional diagram showing injection sites on the buttocks for subcutaneous administration. The left and right buttocks are labeled L and R, each marked with a circular area labeled OK indicating appropriate injection sites.*
FDA Label Image

Figure 12 (Figure 12)

Figure 12 (Figure 12)
An instructional illustration showing the proper preparation for a subcutaneous injection. The image depicts a person swabbing the injection site on the upper thigh or buttock area with an antiseptic wipe before administering the LANREOTIDE ACETATE injection.*
FDA Label Image

Figure 13 (Figure 13)

Figure 13 (Figure 13)
An instructional diagram showing hands preparing a syringe for use, likely related to subcutaneous injection. One hand holds a packaged syringe while the other hand is removing or manipulating a component, demonstrating preparation steps for an injection.*
FDA Label Image

Figure 14 (Figure 14)

Figure 14 (Figure 14)
An instructional diagram showing a hand holding a syringe or injection device and another hand removing a cap or protective cover from the needle or injection tip, indicated by arrows pointing outward.*
FDA Label Image

Figure 15 (Figure 15)

Figure 15 (Figure 15)
An instructional line drawing showing a hand holding a syringe with a label on it, illustrating the proper grip or handling of the LANREOTIDE ACETATE injection syringe for subcutaneous use.*
FDA Label Image

Figure 16 (Figure 16)

Figure 16 (Figure 16)
An instructional diagram showing correct and incorrect techniques for injection. The top image displays a hand giving a subcutaneous injection with a check mark indicating it is correct, while the bottom image shows crossed arms with an X mark indicating an incorrect injection site or method.*
FDA Label Image

Figure 17 (Figure 17)

Figure 17 (Figure 17)
An instructional illustration showing a hand holding a syringe at a 90-degree angle to the skin, demonstrating the technique for subcutaneous injection. The image emphasizes the proper angle and positioning for administering the injection.*
FDA Label Image

Figure 18 (Figure 18)

Figure 18 (Figure 18)
An instructional illustration showing two steps of proper injection technique for a subcutaneous injection. The first panel indicates not to pinch the skin, with an 'X' over the incorrect method. The second panel shows correct use of a thumb and forefinger to pinch the skin gently before injecting, marked with a checkmark.*
FDA Label Image

Figure 19 (Figure 19)

Figure 19 (Figure 19)
An instructional illustration showing a person administering a subcutaneous injection in the upper outer quadrant of the buttock area using a syringe or injector device. The diagram emphasizes proper injection site and technique.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
An instructional illustration showing how to place a LANREOTIDE ACETATE injection box inside a refrigerator. The sequence highlights the placement within the fridge near a milk container, emphasizing proper storage conditions for the medication.*
FDA Label Image

Figure 20 (Figure 20)

Figure 20 (Figure 20)
An instructional diagram showing a hand holding a syringe, preparing to administer a subcutaneous injection, with an arrow indicating the direction of injection. The image demonstrates correct injection technique for a LANREOTIDE ACETATE injection.*
FDA Label Image

Figure 21 (Figure 21)

Figure 21 (Figure 21)
An instructional illustration of a clock indicating a 20-second interval, showing shading from 12 o'clock to 4 o'clock positions. This likely represents a timing step in a procedure related to LANREOTIDE ACETATE subcutaneous injection.*
FDA Label Image

Figure 22 (Figure 22)

Figure 22 (Figure 22)
An instructional illustration showing a hand holding a syringe or injector device against a thigh, indicating the administration of a subcutaneous injection. The image highlights the positioning of the device and the injection site on the leg.*
FDA Label Image

Figure 23 (Figure 23)

Figure 23 (Figure 23)
An instructional diagram showing three sequential steps to unlock or prepare a prefilled injection device for LANREOTIDE ACETATE. The images depict a hand interacting with the device, with arrows indicating the direction of movement for unlocking or removing a cap.*
FDA Label Image

Figure 24 (Figure 24)

Figure 24 (Figure 24)
Illustration showing a hand holding a cloth or wipe, applying it to the lower back or buttock area of a human body, likely demonstrating preparation for a subcutaneous injection site.*
FDA Label Image

Figure 25 (Figure 25)

Figure 25 (Figure 25)
An instructional diagram showing a hand inserting a prefilled syringe device into a disposal container. The image illustrates the proper disposal method for a LANREOTIDE ACETATE subcutaneous injection device by Cipla USA Inc.*
FDA Label Image

Figure 26 (Figure 26)

Figure 26 (Figure 26)
An instructional illustration showing hands rinsing several small spherical objects, likely injection pellets or beads, under running water from a faucet, demonstrating a cleaning or preparation step for LANREOTIDE ACETATE injection.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
An instructional diagram showing a calendar page marked with the date Aug 28 above an image of a medication tray or packaging opened to reveal multiple compartments. The image suggests a scheduled medication or dosing reminder accompanied by the dispensing container.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
An instructional illustration showing an hourglass timing 30 minutes, placed over a pre-filled syringe or injection device. The image suggests waiting for 30 minutes, likely related to preparation or administration steps for the LANREOTIDE ACETATE subcutaneous injection.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
Illustration showing a standing human figure from the back with recommended subcutaneous injection sites marked as 'OK' on the left and right upper buttocks areas. The image is likely intended to guide proper injection administration of LANREOTIDE ACETATE subcutaneous injection.*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
An instructional illustration showing a person lying down on their side with a cushion under their upper leg and a hand positioned near the hip. The caption reads 'Laying Down,' suggesting proper positioning for a subcutaneous injection.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
An instructional illustration showing a hand holding a cluster of small spherical objects under running water from a faucet, likely demonstrating a rinsing or cleaning step in preparation or administration.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
An instructional illustration showing hands opening a peel-back pouch, presumably for accessing the injection product or a related component such as a syringe or needle. This image is likely part of user instructions for LANREOTIDE ACETATE injection by Cipla USA Inc.*
FDA Label Image

Figure 9 (Figure 9)

Figure 9 (Figure 9)
An instructional diagram showing a pre-filled syringe of LANREOTIDE ACETATE injection. The illustration labels the syringe body, needle cap, tray, and expiration date and dose label on the syringe. The syringe is designed for subcutaneous administration.*
FDA Label Image

Carton Label_120mg (Carton Label 120mg)

Carton Label_120mg (Carton Label 120mg)
Carton label for Lanreotide Injection 120 mg/0.5 mL by Cipla USA Inc. The label indicates the product is a subcutaneous injection, with storage instructions to refrigerate at 2°C - 8°C. The label also includes a barcode, revision date, and manufacturer details from Pharmathen International, S.A.*
FDA Label Image

Carton Label_60mg (Carton Label 60mg)

Carton Label_60mg (Carton Label 60mg)
Packaging label for Lanreotide Injection 60 mg/0.2 mL by Cipla USA Inc. It includes storage instructions to refrigerate at 2°C-8°C and the manufacturer's information. The label specifies that each syringe contains 60 mg of lanreotide acetate in 0.2 mL solution for subcutaneous injection. The design shows a white background with blue and orange text elements.*
FDA Label Image

Carton Label_90mg (Carton Label 90mg)

Carton Label_90mg (Carton Label 90mg)
Packaging label for LANREOTIDE ACETATE injection, 90 mg/0.3 mL in a subcutaneous dosage form. The label indicates storage instructions to refrigerate and includes the labeler Cipla USA Inc. The label displays product name, strength, dosage form, and handling instructions with a barcode and contact information for questions.*
FDA Label Image

Pouch Label_120mg (Pouch Label 120mg)

Pouch Label_120mg (Pouch Label 120mg)
Label for Lanreotide Acetate Injection 120 mg/0.5 mL by Cipla USA Inc. The label specifies it is for deep subcutaneous injection, Rx only, and includes storage instructions to refrigerate at 2°C - 8°C (36°F - 46°F) in the original package, protected from light. It also contains administration and safety warnings.*
FDA Label Image

Pouch Label_60mg (Pouch Label 60mg)

Pouch Label_60mg (Pouch Label 60mg)
Label for Lanreotide Injection 60 mg/0.2 mL, a subcutaneous injection from Cipla USA Inc. The label includes dosage strength, administration instructions, storage conditions (refrigerate at 2°C - 8°C), and a barcode. It emphasizes use by healthcare professionals and child safety.*
FDA Label Image

Pouch Label_90mg (Pouch Label 90mg)

Pouch Label_90mg (Pouch Label 90mg)
Packaging label for LANREOTIDE ACETATE injection, 90 mg/0.3 mL strength, intended for deep subcutaneous injection. The label states it is Rx only and manufactured by Cipla USA Inc. It includes storage instructions to refrigerate at 2°C-8°C and to protect from light. The label emphasizes administration by a healthcare professional and advises reading instructions carefully.*
FDA Label Image

Pouch Sticker Label_120mg (Pouch Sticker Label 120mg)

Pouch Sticker Label_120mg (Pouch Sticker Label 120mg)
Label for Lanreotide Injection 120 mg/0.5 mL. It indicates the product is sterile and for single use only, instructing to discard unused portions. Storage instructions advise leaving the injection at room temperature for 30 minutes before administration. Manufactured by Pharmathen International, S.A. in Greece and labeled for Cipla USA, Inc., Warren, NJ.*
FDA Label Image

Pouch Sticker Label_60mg (Pouch Sticker Label 60mg)

Pouch Sticker Label_60mg (Pouch Sticker Label 60mg)
Label for Lanreotide Injection 60 mg/0.2 mL, a subcutaneous injectable drug. The label indicates single use only and to discard any unused portion. It advises leaving the product at room temperature for 30 minutes before administration. Manufactured by Pharmathen International, S.A., Greece, and labeled for Cipla USA Inc. of Warren, NJ.*
FDA Label Image

Pouch Sticker Label_90mg (Pouch Sticker Label 90mg)

Pouch Sticker Label_90mg (Pouch Sticker Label 90mg)
Label for Lanreotide Injection 90 mg/0.3 mL, a single-use sterile subcutaneous injection. Manufactured by Pharmathen International, S.A., Greece, for Cipla USA Inc. Instructions indicate to leave at room temperature for 30 minutes before administration. The label includes discard instructions for unused portions and space for lot and expiration date information.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure diagram displaying the peptide sequence of Lanreotide Acetate with amino acid residues and disulfide bonds, including notation for the acetate component (x(CH3COOH) where x ranges from 1.0 to 2.0).*
FDA Label Image

Syringe Label_120mg (Syringe Label 120mg)

Syringe Label_120mg (Syringe Label 120mg)
Label for Lanreotide Injection 120 mg/0.5 mL subcutaneous injection. The label indicates single-use only and instructs to discard unused portions. Manufactured by Pharmathen International, S.A. in Greece and labeled by Cipla USA Inc., Warren, NJ.*
FDA Label Image

Syringe Label_60mg (Syringe Label 60mg)

Syringe Label_60mg (Syringe Label 60mg)
Label for Lanreotide Injection 60 mg/0.2 mL, a subcutaneous injection. The label indicates it is for single use only and instructs to discard any unused portion. Manufactured by Pharmathen International, S.A., Greece, for Cipla USA, Inc., with an address in Warren, NJ. The label also includes a lot and expiration date area and a non-varnished coding area.*
FDA Label Image

Syringe Label_90mg (Syringe Label 90mg)

Syringe Label_90mg (Syringe Label 90mg)
Label for Lanreotide Injection 90 mg/0.3 mL subcutaneous injection. The label states it is for single use only and instructs to discard any unused portion. It shows the manufacturer as Pharmathen International, S.A., Rodopi, Greece, with manufacturing by Cipla USA, Inc., located in Warren, NJ. The label includes spaces for lot number and expiration date.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.